Factors affecting the prognosis of breast cancer patients with brain metastases

Basit Öğe Kaydı
dc.authoridEralp, Yesim/0000-0001-9603-4755
dc.authoridCicin, Irfan/0000-0002-7584-3868;
dc.authorwosidEralp, Yesim/AAD-7194-2020
dc.authorwosidküçücük, seden/JWP-5854-2024
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.authorwosidSaip, pınar/AAT-1500-2020
dc.contributor.authorSaip, Pinar
dc.contributor.authorCicin, Irfan
dc.contributor.authorEralp, Yesim
dc.contributor.authorKucucuk, Seden
dc.contributor.authorTuzlali, Sitki
dc.contributor.authorKaragol, Hakan
dc.contributor.authorAslay, Isik
dc.date.accessioned2024-06-12T10:55:10Z
dc.date.available2024-06-12T10:55:10Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of this retrospective analysis was to investigate the factors affecting the prognosis of brain metastases in breast cancer patients to identify subgroups which might benefit from prophylactic treatments in future. Seventy-three early and 13 advanced stage patients with known Erb-2 status were included. In 14% of the early stage patients, the first recurrence site was isolated brain metastasis. None of the anthracycline resistant patients had brain metastases as their first recurrence site. The median interval between diagnosis and brain metastasis was 41.5 months (95% CI, 35.79-47.20) in early stage patients. The median interval between the first extracerebral metastases to the brain metastases was 15.5 months (95% CI, 12.24-18.76) in all patients. High histologic and nuclear grade, large tumor, anthracycline resistance were the factors which significantly affected the early appearance of brain metastases but only advanced age (>= 55 years, P = .035) correlated with isolated brain metastasis. Progression with isolated brain metastases was significantly higher in responsive ErbB-2 positive population (P = .036) and none of other pathological factors was associated with isolated brain metastasis in advanced stage. The median survival after brain metastasis in patients with brain metastasis as first recurrence was longer than the patients with brain metastasis after other organ metastasis (13 months vs 2 months P = .003). The median survival following brain metastases in complete responsive patients was higher than the others (24 months vs 6 months, P = .002). Therefore, response to systemic treatment was more determinative in the development of isolated brain metastases than clinical and pathologic features. ErbB-2 should be emphasized in prophylactic treatment strategies. Prophylactic cranial radiotherapy may be an effective treatment option for metastatic patients with complete responsive disease and with controlled ErbB-2 positive disease. (C) 2008 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.breast.2008.03.004
dc.identifier.endpage458en_US
dc.identifier.issn0960-9776
dc.identifier.issn1532-3080
dc.identifier.issue5en_US
dc.identifier.pmid18455400en_US
dc.identifier.scopus2-s2.0-53149144684en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage451en_US
dc.identifier.urihttps://doi.org/10.1016/j.breast.2008.03.004
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19321
dc.identifier.volume17en_US
dc.identifier.wosWOS:000260896700004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherChurchill Livingstoneen_US
dc.relation.ispartofBreasten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Canceren_US
dc.subjectBrain Metastasisen_US
dc.subjectPrognostic Factorsen_US
dc.subjectNervous-System Metastasesen_US
dc.subjectPhase-Iien_US
dc.subjectTrastuzumaben_US
dc.subjectTemozolomideen_US
dc.subjectInvolvementen_US
dc.subjectEpirubicinen_US
dc.subjectLapatiniben_US
dc.subjectReceptoren_US
dc.subjectTherapyen_US
dc.subjectWomenen_US
dc.titleFactors affecting the prognosis of breast cancer patients with brain metastasesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu